How Profitable is the HPV Vaccine?

Making Cents (and Dollars) of Gardasil

Merck/Gardasil Revenue for 2019

(bolded for emphasis by Rodef Shalom 613)

Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results

Merck Press Release
February 5, 2020

“Performance in vaccines for the fourth quarter reflects the negative impact of borrowing doses of GARDASIL 9 from the CDC Pediatric Vaccine Stockpile as discussed above, partially offset by higher demand in Europe and China, as well as higher demand and pricing in the United States. Excluding the borrowing-related activity in both periods, GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] and GARDASIL 9 sales grew 15% in the quarter, including a 1% negative impact from foreign exchange.“

∼∼∼∼∼∼∼

Merck’s Gardasil blockbuster sales prompt $1B plant expansion

FiercePharma
May 8, 2019
Erick Palmer

‘“In recent years, HPV vaccine recommendations and goals have changed and countries around the world have enacted new or expanded vaccination programs, which have created an unprecedented increase in global demand for vaccines,” spokeswoman Pam Eisele told FiercePharma in an email today. “We are significantly ramping up our production capacity, and as we previously disclosed investing $16 billion in capital projects over the next five years, with a sizable portion dedicated to vaccine expansion. “

“The news comes shortly after the drugmaker reported that sales of its Gardasil HPV vaccines soared 31% to $838 million in the first quarter, powered to a large degree by an ongoing commercial launch in China. Worldwide sales for 2018 topped $3.15 billion, far outpacing the previous year sales of $2.31 billion—numbers that executives called “unprecedented.”’

(Bolded for emphasis by Rodef Shalom 613)
Read more

∼∼∼∼∼∼∼

The Creating of an HPV Industry

SaneVax Inc.
April 2011
Norma Erickson

“Key points:
• Human Papillomavirus (HPV) DNA discovered in cervical cancer in 1983‐1984
• HPV vaccine patents 1991‐1993
• Government becomes partners in HPV vaccine (NCI and Merck) 2006
• NCI and FDA: In effect the business tactics are to “market Gardasil by fear” as Gardasil gets quasi‐cancer vaccine status – this misconception is allowed to be perpetuated uncorrected with far reaching consequences. This is supported by in effect “marketing by confusion”: via the creation of a not too sensitive, not too specific HPV DNA Test and perpetuated by “confusion” via creating the ASCUS‐LSIL Triage Study (ALTS) program to perpetuate the confusion
• Adverse events post Gardasil vaccination rise and higher than any other vaccine tracked on VAERS database
• Gardasil contaminated with recombinant HPV DNA bounded to adjuvant – possible explanation of substantial and diverse adverse events 2011″